Searchable abstracts of presentations at key conferences in endocrinology

ea0011p523 | Endocrine tumours and neoplasia | ECE2006

Glucocorticoid receptor gene N363S variant in patients with clinically inapparent adrenal adenomas

Reimondo G , Micossi I , Giachino D , Bovio S , Allasino B , Daffara F , Angeli A , Terzolo M , De Marchi M

N363S polymorphism of the human glucocorticoid receptor gene has been detected in the heterozygous state in approximately 3–9% of general European population. This variant has been associated with increased sensitivity to glicocorticoids, increased insulin response to dexamethasone, a tendency towards lower bone mineral density, increased body mass index, and unstable angina. However, other reports found no associations with these pathological conditions. We assessed the ...

ea0029oc7.3 | Adrenal Clinical | ICEECE2012

Ribonucleotide reductase large subunit (RRM1) gene expression predicts efficacy of adjuvant mitotane in adrenocortical cancer

Volante M. , Terzolo M. , Fassnacht M. , Rapa I. , Germano A. , Sbiera S. , Daffara F. , Sperone P. , Scagliotti G. , Allolio B. , Papotti M. , Berruti A.

Purpose: Mitotane is the reference systemic therapy for adrenocortical carcinoma (ACC), but its mechanism of action and possible predictors of treatment response remain poorly defined. Our aim was to evaluate the gene expression of ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome and response to mitotane.Experimental design: Forty-five and 47 tiss...

ea0026p27 | Adrenal cortex | ECE2011

Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

Ardito A , Al Ghuzian A , Fassnacht M , Daffara F , Leboulleux S , Wortmann S , Zaggia B , De Francia S , Volante Marco , Gonzaga Luigi , Berruti Alfredo , Allolio Bruno , Baudin Eric , Terzolo Massimo

We have demonstrated that adjuvant mitotane prolong recurrence free survival (RFS) in patients with radically resected ACC. Aim of the present study was to correlate mitotane levels with patient outcome in an adjuvant setting in 3 different referral centres in Europe. There were 120 patients (45 W, 75 M, median age 44 years, range 16–76) radically resected for ACC who were treated adjuvantly with mitotane from 1996 to 2010. ACC was stage I in 10 cases, II in 73, III in 31...